bimagrumab vs REGN20934

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Activin/myostatin type II receptor · full Obesity pipeline

bimagrumab

Developed by Eli Lilly and partners

Phase 2 in Obesitymonoclonal antibody
Partial signal

NCT05616013 · Phase 2 · completed

This randomized, double-blind, placebo-controlled trial enrolled 507 adults and used a hard clinical primary endpoint, change in body weight at Week 48. The primary endpoint comparison showed a statistically significant advantage for most active treatment combinations over placebo, including the highest-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg), but the 10 mg/kg bimagrumab monotherapy arm missed significance, yielding a mixed primary endpoint result. Because the primary endpoint was not uniformly met across the multiple prespecified comparisons, the overall evidence is moderate despite the strong design.

Reported efficacy

Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17) (mixed)

Result source: NCT05616013

REGN20934

Developed by Regeneron Pharmaceuticals

Phase 1 in Obesitymonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT07594093 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbimagrumabREGN20934
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)-9 vs 0.5−9.4 vs placebo10 mg/kg · wk 52 · n 36NCT03005288
11 other results
  • -5.0 vs -0.9 10 mg/kg · wk 24 · n 36 · Phase 2 · secondary NCT03005288
  • -13.0 vs -14.7 30 mg/kg · wk 72 · n 31 · Phase 2 · secondary NCT05616013
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -10.6 vs -13.6 30 mg/kg · wk 48 · n 37 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
—Not reported

Body weight, % change

bimagrumab
—Not reported
REGN20934
—Not reported

Weight loss of 5% or more

bimagrumab
—Not reported
REGN20934
—Not reported

Weight loss of 10% or more

bimagrumab
—Not reported
REGN20934
—Not reported

Waist circumference, change (cm)

bimagrumab
-9 vs 0.5−9.4 vs placebo10 mg/kg · wk 52 · n 36NCT03005288
11 other results
  • -5.0 vs -0.9 10 mg/kg · wk 24 · n 36 · Phase 2 · secondary NCT03005288
  • -13.0 vs -14.7 30 mg/kg · wk 72 · n 31 · Phase 2 · secondary NCT05616013
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -10.6 vs -13.6 30 mg/kg · wk 48 · n 37 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
REGN20934
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

REGN20934: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. bimagrumab: 4 of 4 rows · REGN20934: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbimagrumab
Dropout rate
52.6%30 mg/kga
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 9 more results
33.9%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
38.6%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
50%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
37.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
30.8%10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
65.5%30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
15.8%30 mg/kga
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 9 more results
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
1.8%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
14.3%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
5.4%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.8%10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
10.3%30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
Serious AEs
14%30 mg/kga
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 9 more results
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.7%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.5%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
14.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
8.1%10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
—30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
62.1%30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
36.8%30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
33.3%30mg/kg
NCT01433263 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
30 mg/kga
muscle spasms 71.9%
diarrhoea 50.9%
acne 49.1%
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 8 more results
30 mg/kg + 1.0 mg
muscle spasms 64.3%
acne 55.4%
diarrhoea 44.6%
NCT05616013 · Phase 2 · combination · Obesity · phase 2
30 mg/kg + 2.4 mg
muscle spasms 63.6%
acne 52.7%
diarrhoea 49.1%
NCT05616013 · Phase 2 · combination · Obesity · phase 2
10 mg/kg + 1.0 mg
muscle spasms 57.1%
diarrhoea 48.2%
acne 42.9%
NCT05616013 · Phase 2 · combination · Obesity · phase 2
10 mg/kg + 2.4 mg
muscle spasms 65.5%
nausea 61.8%
diarrhoea 52.7%
NCT05616013 · Phase 2 · combination · Obesity · phase 2
10 mg/kg
diarrhoea 40.5% (placebo 10.5%)
muscle spasms 40.5% (placebo 2.6%)
upper respiratory tract infection 16.2% (placebo 13.2%)
NCT03005288 · Phase 2 · registry result, not featured evidence
30mg/kg
fatigue 20.7% (placebo 10.7%)
diarrhoea 17.2% (placebo 10.7%)
nausea 17.2% (placebo 3.6%)
NCT01433263 · Phase 2 · registry result, not featured evidence
30mg/kg
fatigue 21.1% (placebo 10.7%)
anaemia 10.5% (placebo 21.4%)
neutropenia 10.5% (placebo 10.7%)
NCT01433263 · Phase 2 · registry result, not featured evidence
30mg/kg
diarrhoea 23.8% (placebo 10.7%)
anaemia 14.3% (placebo 21.4%)
amylase increased 9.5% (placebo 0%)
NCT01433263 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

bimagrumab

Weight -9.25 vs -9.76 semaglutide kg @ 48wk30 mg/kg
absolute change · kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 6 more results
-13.86 vs -9.76 semaglutide kg @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-17.79 vs -9.76 semaglutide kg @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-12.73 vs -9.76 semaglutide kg @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-14.31 vs -9.76 semaglutide kg @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-3.99 vs -0.57 placebo kg @ 24wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
-5.9 vs -0.79 placebo kg @ 48wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
Waist Circumference Change -10.64 vs -10.57 semaglutide cm @ 48wk30 mg/kg
absolute change · cm
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 11 more results
-15.84 vs -10.57 semaglutide cm @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-19.03 vs -10.57 semaglutide cm @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-13.04 vs -10.4 semaglutide cm @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-18.21 vs -10.4 semaglutide cm @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-21.26 vs -10.4 semaglutide cm @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-14.63 vs -10.57 semaglutide cm @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-16.55 vs -10.57 semaglutide cm @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-15.59 vs -10.4 semaglutide cm @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-18.1 vs -10.4 semaglutide cm @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-5.04 vs -0.95 placebo cm @ 24wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
-9 vs 0.45 placebo cm @ 52wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
Body Fat Mass -11.86 vs -7.49 semaglutide kg @ 48wk30 mg/kg
absolute change · kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 21 more results
-15.33 vs -7.49 semaglutide kg @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-19.3 vs -7.49 semaglutide kg @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-13.24 vs -7.66 semaglutide kg @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-16.72 vs -7.66 semaglutide kg @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-21.24 vs -7.66 semaglutide kg @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-9.84 vs -7.54 semaglutide kg @ 48wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-14.16 vs -7.54 semaglutide kg @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-16.87 vs -7.54 semaglutide kg @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-10.24 vs -6.49 semaglutide kg @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-14.95 vs -6.49 semaglutide kg @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-19.43 vs -6.49 semaglutide kg @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-14.17 vs -7.49 semaglutide kg @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-15.93 vs -7.49 semaglutide kg @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-15.85 vs -7.66 semaglutide kg @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-17.52 vs -7.66 semaglutide kg @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-12.85 vs -7.54 semaglutide kg @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-14.71 vs -7.54 semaglutide kg @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-13.94 vs -6.49 semaglutide kg @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-14.86 vs -6.49 semaglutide kg @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-7.49 vs -0.18 placebo kg @ 48wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
-5.37 vs -0.18 placebo kg @ 24wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
Body Fat -25.23% (n=36) vs -18.36% (n=45) semaglutide @ 48wk30 mg/kg
percent change · % of baseline
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 19 more results
-34.42% (n=42) vs -18.36% (n=45) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-42.06% (n=43) vs -18.36% (n=45) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-28.35% (n=27) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-37.26% (n=41) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-45.42% (n=34) vs -18.97% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-5.7% (n=37) vs -3.8% (n=45) semaglutide @ 48wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-8.39% (n=43) vs -3.8% (n=45) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-9.33% (n=43) vs -3.8% (n=45) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-5.65% (n=31) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-8.71% (n=42) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-11.33% (n=39) vs -3.06% (n=40) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-30.6% (n=42) vs -18.36% (n=45) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-35.85% (n=40) vs -18.36% (n=45) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-33.58% (n=32) vs -18.97% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-39.46% (n=38) vs -18.97% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-7.03% (n=41) vs -3.8% (n=45) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-8.47% (n=40) vs -3.8% (n=45) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-7.43% (n=34) vs -3.06% (n=40) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-8.29% (n=39) vs -3.06% (n=40) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
Waist Circumference Reduction 5 cm 78.4% (n=37) vs 66.7% (n=45) semaglutide @ 48wk30 mg/kg
responder rate · % of participants
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
90.7% (n=43) vs 66.7% (n=45) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
97.7% (n=43) vs 66.7% (n=45) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
95.1% (n=41) vs 66.7% (n=45) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
100% (n=39) vs 66.7% (n=45) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
Lean Mass 1.19 vs -2.86 semaglutide kg @ 48wk30 mg/kg
absolute change · kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 21 more results
-0.65 vs -2.86 semaglutide kg @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.43 vs -2.86 semaglutide kg @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
1.28 vs -2.78 semaglutide kg @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-0.79 vs -2.78 semaglutide kg @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.84 vs -2.78 semaglutide kg @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.68 vs -3.4 semaglutide kg @ 48wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-2.73 vs -3.4 semaglutide kg @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-4.62 vs -3.4 semaglutide kg @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.45 vs -4.34 semaglutide kg @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-3.95 vs -4.34 semaglutide kg @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-4.5 vs -4.34 semaglutide kg @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.28 vs -2.86 semaglutide kg @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.12 vs -2.86 semaglutide kg @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.04 vs -2.78 semaglutide kg @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.78 vs -2.78 semaglutide kg @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.73 vs -3.4 semaglutide kg @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-3.15 vs -3.4 semaglutide kg @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-3.32 vs -4.34 semaglutide kg @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-5.79 vs -4.34 semaglutide kg @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
1.72 vs 0.23 placebo kg @ 24wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
1.7 vs -0.44 placebo kg @ 48wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
Lean Mass 2.39% (n=36) vs -5.23% (n=45) semaglutide @ 48wk30 mg/kg
percent change · % of baseline
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 19 more results
-1% (n=42) vs -5.23% (n=45) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.51% (n=43) vs -5.23% (n=45) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
2.71% (n=27) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-1.38% (n=41) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-3% (n=34) vs -5.09% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
5.35% (n=37) vs 4.02% (n=45) semaglutide @ 48wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
7.23% (n=43) vs 4.02% (n=45) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
8.91% (n=43) vs 4.02% (n=45) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
4.65% (n=31) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
6.79% (n=42) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
10.64% (n=39) vs 2.8% (n=40) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.21% (n=42) vs -5.23% (n=45) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.92% (n=40) vs -5.23% (n=45) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-1.96% (n=32) vs -5.09% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.89% (n=38) vs -5.09% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
6.83% (n=41) vs 4.02% (n=45) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
8.29% (n=40) vs 4.02% (n=45) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
6.52% (n=34) vs 2.8% (n=40) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
6.89% (n=39) vs 2.8% (n=40) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
Appendicular Lean Mass 2.47% (n=36) vs -5.68% (n=45) semaglutide @ 48wk30 mg/kg
percent change · % of baseline
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 9 more results
-1.74% (n=42) vs -5.68% (n=45) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.28% (n=43) vs -5.68% (n=45) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
2.78% (n=27) vs -6.24% (n=38) semaglutide @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
-2.29% (n=41) vs -6.24% (n=38) semaglutide @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.4% (n=34) vs -6.24% (n=38) semaglutide @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.31% (n=42) vs -5.68% (n=45) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.22% (n=40) vs -5.68% (n=45) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-2.3% (n=32) vs -6.24% (n=38) semaglutide @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-3.87% (n=38) vs -6.24% (n=38) semaglutide @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
HbA1c -0.17% (n=33) vs -0.34% (n=44) semaglutide @ 48wk30 mg/kg
absolute change · percentage points
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 6 more results
-0.44% (n=39) vs -0.34% (n=44) semaglutide @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-0.48% (n=43) vs -0.34% (n=44) semaglutide @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-0.37% (n=40) vs -0.34% (n=44) semaglutide @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-0.56% (n=41) vs -0.34% (n=44) semaglutide @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
-0.85% (n=36) vs 0.28% (n=36) placebo @ 24wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
-0.76% (n=36) vs 0.04% (n=36) placebo @ 48wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence
SF-36 Physical Functioning 11.61 vs 11.5 semaglutide T-score @ 24wk30 mg/kg
absolute change · T-score
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 14 more results
12.71 vs 11.5 semaglutide T-score @ 24wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.45 vs 11.5 semaglutide T-score @ 24wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
13.41 vs 11.68 semaglutide T-score @ 48wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
15.27 vs 11.68 semaglutide T-score @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
18.25 vs 11.68 semaglutide T-score @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
15.9 vs 14.06 semaglutide T-score @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
17.04 vs 14.06 semaglutide T-score @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
20.91 vs 14.06 semaglutide T-score @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.2 vs 11.5 semaglutide T-score @ 24wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.75 vs 11.5 semaglutide T-score @ 24wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
16.34 vs 11.68 semaglutide T-score @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
15.14 vs 11.68 semaglutide T-score @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
17.36 vs 14.06 semaglutide T-score @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
14.41 vs 14.06 semaglutide T-score @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
SF-36 Total 9.7 vs 11.95 semaglutide score @ 24wk30 mg/kg
absolute change · score
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
show 14 more results
13.82 vs 11.95 semaglutide score @ 24wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
13.31 vs 11.95 semaglutide score @ 24wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
11.31 vs 13.62 semaglutide score @ 48wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
17.03 vs 13.62 semaglutide score @ 48wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
17.69 vs 13.62 semaglutide score @ 48wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.28 vs 13.84 semaglutide score @ 72wk30 mg/kg
NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2
18.26 vs 13.84 semaglutide score @ 72wk30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
17.85 vs 13.84 semaglutide score @ 72wk30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
12.96 vs 11.95 semaglutide score @ 24wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
10.09 vs 11.95 semaglutide score @ 24wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
15.99 vs 13.62 semaglutide score @ 48wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
16.42 vs 13.62 semaglutide score @ 48wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
16.98 vs 13.84 semaglutide score @ 72wk10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
14.37 vs 13.84 semaglutide score @ 72wk10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · combination · Obesity · phase 2
BMI -1.5 vs -0.17 placebo kg @ 24wk10 mg/kg
absolute change · kg
NCT03005288 · Phase 2 · registry result, not featured evidence
show 1 more result
-2.19 vs -0.28 placebo kg @ 48wk10 mg/kg
NCT03005288 · Phase 2 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimagrumab's landscape · REGN20934's landscape